Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL182685 | 0.74 | HSD17B10 (0.31) | HSD17B10 | |
| SCHEMBL13506940 | 0.72 | — | — | |
| SCHEMBL180596 | 0.71 | — | — | |
| SCHEMBL141255 | 0.71 | HSD17B10 (0.44) | HSD17B10 | |
| SCHEMBL21750445 | 0.70 | HSD17B10 (0.33) | HSD17B10 | |
| SCHEMBL3955091 | 0.68 | — | — | |
| SCHEMBL20055717 | 0.68 | HSD17B10 (0.42) | HSD17B10 | |
| SCHEMBL7598 | 0.68 | — | — | |
| Ammonia Solution, Strong SCHEMBL6053342 | 0.68 | — | — | |
| SCHEMBL2296938 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0483667-B1 | Cyclic imino derivatives, process for their preparation and drugs containing them | THOMAE GMBH DR K (DE) | 1998-02-04 | — | — | EP | claimed |
| US-5489693-A | ANTICOAGULANTS | DR. KARK THOMAE, GMBH (DE) | 1996-02-06 | — | — | US | claimed |
| US-11197858-B2 | Substituted amines for treating cardiac diseases | CARDURION PHARMACEUTICALS, LLC (US) | 2021-12-14 | — | — | US | disclosed |
| US-20200230137-A1 | SUBSTITUTED AMINES FOR TREATING CARDIAC DISEASES | CARDURION PHARMACEUTICALS, LLC (US) | 2020-07-23 | — | — | US | disclosed |
| EP-3600327-A1 | HETEROCYCLIC COMPOUND | Cardurion Pharmaceuticals, LLC (US) | 2020-02-05 | — | — | EP | disclosed |
| US-10543212-B2 | Substituted amines for treating cardiac diseases | CARDURION PHARMACEUTICALS, LLC (US) | 2020-01-28 | — | — | US | disclosed |
| WO-2018183112-A1 | HETEROCYCLIC COMPOUND | CARDURION PHARMACEUTICALS, LLC (US) | 2018-10-04 | — | — | WO | disclosed |
| US-20180280389-A1 | HETEROCYCLIC COMPOUND | CARDURION PHARMACEUTICALS, LLC (US) | 2018-10-04 | — | — | US | disclosed |
| EP-3105228-B1 | HETEROCYCLIC COMPOUNDS USEFUL IN THE TREATMENT OF DIABETES AND OBESITY | TAKEDA PHARMACEUTICALS CO (JP) | 2018-09-26 | — | — | EP | disclosed |
| US-10023544-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-07-17 | — | — | US | disclosed |
| EP-3105228-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2016-12-21 | — | — | EP | disclosed |
| WO-2008011131-A2 | AMIDE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-01-24 | — | — | WO | disclosed |
| US-20060089355-A1 | Methods of treating alzheimer's disease using aromatically substituted w-amino-alkanoic acid amides and alkanoic acid diamides | ELAN PHARMACEUTICALS, INC. | 2006-04-27 | — | — | US | disclosed |
| US-5641778-A | EXHIBIT RENIN-INHIBITING PROPERTIES AND CAN BE USED AS ANTIHYPERTENSIVE AGENTS | CIBA-GEIGY CORPORATION (US) | 1997-06-24 | — | — | US | disclosed |
| US-5591769-A | PYRROLIDINE DERIVATIVES; ANTICOAGULANTS | KARL THOMAE GMBH (DE) | 1997-01-07 | — | — | US | disclosed |
| US-5541343-A | ANTIAGGLOMERANTS FOR CELLS OR ANTICOAGULANTS | KARL THOMAE GMBH (DE) | 1996-07-30 | — | — | US | disclosed |
| US-5489693-A | ANTICOAGULANTS | DR. KARK THOMAE, GMBH (DE) | 1996-02-06 | — | — | US | disclosed |
| US-5455348-A | Anticoagulants | Thomae, Karl (DE) | 1995-10-03 | — | — | US | disclosed |
| US-3993683-A | ANTITHROMBOTIC, ANTICHOLESTEREMICS, ANTICOAGULANTS | BOEHRINGER INGELHEIM GMBH (DT) | 1976-11-23 | — | — | US | disclosed |
| US-3993683-A | ANTITHROMBOTIC, ANTICHOLESTEREMICS, ANTICOAGULANTS | BOEHRINGER INGELHEIM GMBH (DT) | 1976-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11197858-B2 | Substituted amines for treating cardiac diseases | TNNI3, CALM1, CAMK2G | HSD17B10 2860/4885 |
| US-20180280389-A1 | HETEROCYCLIC COMPOUND | CALM1, CAMK2B, CAMK2G | HSD17B10 2392/4885 |
| US-20060089355-A1 | Methods of treating alzheimer's disease using aromatically substituted w-amino-alkanoic acid amides and alkanoic acid diamides | APP, BACE1, BACE2 | HSD17B10 1219/4885 |
| US-10543212-B2 | Substituted amines for treating cardiac diseases | TNNI3, CALM1, CAMK2G | HSD17B10 2860/4885 |
| US-20200230137-A1 | SUBSTITUTED AMINES FOR TREATING CARDIAC DISEASES | TNNI3, CALM1, CAMK2G | HSD17B10 2860/4885 |
| US-10023544-B2 | Heterocyclic compound | MMP2, DPP4, TMPRSS15 | HSD17B10 351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.